Evidence map›Paper›PMID 32395351›Full record

ArticleInternational journal of hepatology2020

Impact of Treatment with Direct Acting Antiviral Drugs on Glycemic Control in Patients with Hepatitis C and Diabetes Mellitus.

Pradeep Kumar Mada, Matthew E Malus, Arvin Parvathaneni, Bing Chen, Gabriel Castano, Sharon Adley, Maureen Moore, Michinari Hieda, Mohammed J Alam, Mark Feldman and 1 more

Open access · goldAbstract read
In one paragraph

Article in International journal of hepatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Pradeep Kumar MadaInternal Medicine Department, Texas Health Presbyterian Hospital, Dallas, TX, USA.ORCID https://orcid.org/0000-0001-7855-7982
Matthew E MalusInternal Medicine, Louisiana State University Health Sciences Center-Shreveport, Shreveport, LA, USA.
Arvin ParvathaneniNeurology, Louisiana State University Health Sciences Center-Shreveport, Shreveport, LA, USA.
Bing ChenInternal Medicine, Louisiana State University Health Sciences Center-Shreveport, Shreveport, LA, USA.
Gabriel CastanoPediatrics, UT Health Sciences Center, San Antonio, USA.
Sharon AdleyInfectious Diseases, Louisiana State University Health Sciences Center-Shreveport, Shreveport, LA, USA.
Maureen MooreInfectious Diseases, Louisiana State University Health Sciences Center-Shreveport, Shreveport, LA, USA.
Michinari HiedaInstitute for Exercise and Environmental Medicine, University of Texas Southwestern Medical Center, USA.ORCID https://orcid.org/0000-0003-3434-6184
Mohammed J AlamInfectious Diseases, Louisiana State University Health Sciences Center-Shreveport, Shreveport, LA, USA.
Mark FeldmanInternal Medicine Department, Texas Health Presbyterian Hospital, Dallas, TX, USA.ORCID https://orcid.org/0000-0003-4448-3991
John William KingInfectious Diseases, Louisiana State University Health Sciences Center-Shreveport, Shreveport, LA, USA.
Louisiana State University Health Sciences Center Shreveport · USTexas Health Dallas · USInstitute for Exercise and Environmental Medicine · USThe University of Texas Health Science Center at San Antonio · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo assess the effect of treating chronic hepatitis C virus (HCV) infection with direct acting antiviral drugs (DAAs) on glycemic control in patients with concomitant diabetes mellitus (DM).

methodsWe performed a retrospective case-control study in a viral hepatitis ambulatory clinic in Shreveport, Louisiana, during the period 11/01/2014 to 12/31/2017. All the clinic patient ages 18 years and above with treatment-naïve/biopsy-proven chronic hepatitis C and DM (hemoglobin A1C level ≥ 6.5%) who were eligible for treatment were included in the study. Of 118 such patients, 59 were treated with oral DAAs for 8-12 weeks with the goal of achieving a sustained virologic response (SVR). A control group of 59 patients did not receive treatment for their hepatitis C and was followed in the clinic. Patients in the control group did not receive treatment either due to insurance issues or refusal of hepatitis C treatment.

resultsFifty-five of the 59 patients treated with DAAs (93%) achieved a SVR. Six months after treatment completion, their mean ± SEM HbA1C level had decreased by 1.1 ± 0.03% (

conclusionThis controlled study demonstrated that treatment of chronic hepatitis C with DAAs results in statistically significant and meaningful reductions in hemoglobin A1C levels in patients with coexisting diabetic mellitus if a SVR is achieved.

Identifiers

PMID32395351
PMCPMC7201615
OpenAlexW3000468036

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.